Poster

Changes in Health Care Resource Utilization Following Initiation of Ustekinumab in Members with Inflammatory Bowel Disease in a Medicaid Population

Wilson Haong, PharmD, MBA Managed Care Pharmacy Resident
Mckenzie Taylor, PharmD Headshot
Mckenzie Taylor, PharmD Managed Care Pharmacy Resident, Clinical Pharmacy Services
Mark Tesell, PharmD, BCPS Headshot
Mark Tesell, PharmD, BCPS
Caroline J. Alper, MD
Thomas Pomfret, PharmD, MPH, BCPS Headshot
Thomas Pomfret, PharmD, MPH, BCPS Clinical Consultant Pharmacist Team Lead and Residency Program Director, Clinical Pharmacy Services
Karen Clements, ScD Headshot
Karen Clements, ScD Senior Project Director, Research and Evaluation
Bonnie C. Greenwood, PharmD, BCPS Headshot
Bonnie C. Greenwood, PharmD, BCPS Director, Clinical Programs, Clinical Pharmacy Services
Mylissa Price, MPH, RPh Headshot
Mylissa Price, MPH, RPh Director - Clinical Account Management, Clinical Pharmacy Services
Diala Nicolas, PharmD, BCPS
Kimberly Lenz, PharmD, MBA, FAMCP Headshot
Kimberly Lenz, PharmD, MBA, FAMCP Senior Pharmacy Director, MassHealth/Office of Clinical Affairs

This study aimed to identify the economic burden of inflammatory bowel disease (IBD) by comparing mean annual IBD-related medical costs and events (e.g., inpatient hospitalizations, emergency department visits, and outpatient visits) for MassHealth members before and after ustekinumab initiation. Initiation of treatment with ustekinumab was not associated with statistically significant changes in mean annual IBD-related medical costs or events in the overall study population; however, increased medical costs were observed among patients in a high- dose cohort. 

UMASS_Poster_CPS_AMCP-2022_ChangesHCRUFIUMBDMedPop_v6_2022-FINAL.pdf